CN109053630B - Benzothiazole derivative and application thereof - Google Patents
Benzothiazole derivative and application thereof Download PDFInfo
- Publication number
- CN109053630B CN109053630B CN201810958721.1A CN201810958721A CN109053630B CN 109053630 B CN109053630 B CN 109053630B CN 201810958721 A CN201810958721 A CN 201810958721A CN 109053630 B CN109053630 B CN 109053630B
- Authority
- CN
- China
- Prior art keywords
- thiazol
- benzo
- fluoro
- cyclopropanecarboxamide
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 230000017074 necrotic cell death Effects 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims abstract description 23
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims abstract description 22
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims abstract description 21
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 11
- 230000002458 infectious effect Effects 0.000 claims abstract description 10
- 230000003412 degenerative effect Effects 0.000 claims abstract description 9
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 230000000302 ischemic effect Effects 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 5
- 230000000451 tissue damage Effects 0.000 claims abstract description 5
- 231100000827 tissue damage Toxicity 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract 2
- -1 4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy Chemical group 0.000 claims description 176
- 125000005605 benzo group Chemical group 0.000 claims description 148
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 138
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 107
- 238000002360 preparation method Methods 0.000 claims description 37
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 206010024641 Listeriosis Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 4
- 206010039438 Salmonella Infections Diseases 0.000 claims description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 4
- 201000003229 acute pancreatitis Diseases 0.000 claims description 4
- 206010039447 salmonellosis Diseases 0.000 claims description 4
- 208000037816 tissue injury Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- RIVQMLWSKYAVFY-UHFFFAOYSA-N BrC=1C=C(C=CC=1)NC(NC=1C=C(C=CC=1F)OC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1)=O Chemical compound BrC=1C=C(C=CC=1)NC(NC=1C=C(C=CC=1F)OC1=CC2=C(N=C(S2)NC(=O)C2CC2)C=C1)=O RIVQMLWSKYAVFY-UHFFFAOYSA-N 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims description 3
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims description 3
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims description 3
- 229940047889 isobutyramide Drugs 0.000 claims description 3
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 17
- 239000012453 solvate Substances 0.000 abstract description 11
- 239000000651 prodrug Substances 0.000 abstract description 7
- 229940002612 prodrug Drugs 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 390
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 154
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 96
- 239000003208 petroleum Substances 0.000 description 77
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 74
- 239000000243 solution Substances 0.000 description 73
- 239000007787 solid Substances 0.000 description 57
- 239000003480 eluent Substances 0.000 description 56
- 238000010898 silica gel chromatography Methods 0.000 description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 50
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- 229910052757 nitrogen Inorganic materials 0.000 description 46
- 239000000203 mixture Substances 0.000 description 42
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- BLXXCCIBGGBDHI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1 BLXXCCIBGGBDHI-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 235000011054 acetic acid Nutrition 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- IZXLNEHPKQVCAE-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical group OC(=O)CC1=CC=CC(C(F)(F)F)=C1F IZXLNEHPKQVCAE-UHFFFAOYSA-N 0.000 description 4
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012964 benzotriazole Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ZWXDAANEJMSCEX-UHFFFAOYSA-N 1-(3-anilinophenyl)ethanone Chemical group CC(=O)C1=CC=CC(NC=2C=CC=CC=2)=C1 ZWXDAANEJMSCEX-UHFFFAOYSA-N 0.000 description 2
- NHNFWACSJQAMDR-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]cyclopropane-1-carboxylic acid Chemical group C=1C=CC(C(F)(F)F)=CC=1C1(C(=O)O)CC1 NHNFWACSJQAMDR-UHFFFAOYSA-N 0.000 description 2
- OTTPBKINJOYJGW-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)acetic acid Chemical group CC1=CC=C(CC(O)=O)C=C1C OTTPBKINJOYJGW-UHFFFAOYSA-N 0.000 description 2
- BKHAMYPTSCXFRM-UHFFFAOYSA-N 2-(3-amino-4-fluorophenoxy)-5-nitrobenzonitrile Chemical compound C1=C(F)C(N)=CC(OC=2C(=CC(=CC=2)[N+]([O-])=O)C#N)=C1 BKHAMYPTSCXFRM-UHFFFAOYSA-N 0.000 description 2
- YEAUYVGUXSZCFI-UHFFFAOYSA-N 2-(3-fluorophenyl)acetic acid Chemical group OC(=O)CC1=CC=CC(F)=C1 YEAUYVGUXSZCFI-UHFFFAOYSA-N 0.000 description 2
- TYOCDHCKTWANIR-UHFFFAOYSA-N 2-[2-(trifluoromethyl)phenyl]acetic acid Chemical group OC(=O)CC1=CC=CC=C1C(F)(F)F TYOCDHCKTWANIR-UHFFFAOYSA-N 0.000 description 2
- JZEWYZAIWWNAPZ-UHFFFAOYSA-N 2-[2-chloro-3-(trifluoromethyl)phenyl]acetic acid Chemical group OC(=O)CC1=CC=CC(C(F)(F)F)=C1Cl JZEWYZAIWWNAPZ-UHFFFAOYSA-N 0.000 description 2
- PAWSKKHEEYTXSA-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]acetic acid Chemical group OC(=O)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PAWSKKHEEYTXSA-UHFFFAOYSA-N 0.000 description 2
- MGQPQAYFSXCYPW-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical group OC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 MGQPQAYFSXCYPW-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- MQVISALTZUNQSK-UHFFFAOYSA-N 2-pyridin-2-ylacetic acid;hydrochloride Chemical group Cl.OC(=O)CC1=CC=CC=N1 MQVISALTZUNQSK-UHFFFAOYSA-N 0.000 description 2
- LEGPZHPSIPPYIO-UHFFFAOYSA-N 3-Methoxyphenylacetic acid Chemical group COC1=CC=CC(CC(O)=O)=C1 LEGPZHPSIPPYIO-UHFFFAOYSA-N 0.000 description 2
- VJCSFNNTQGRAKH-UHFFFAOYSA-N 3-amino-4-fluorophenol Chemical compound NC1=CC(O)=CC=C1F VJCSFNNTQGRAKH-UHFFFAOYSA-N 0.000 description 2
- FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical group OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 2
- FQXQBFUUVCDIRK-UHFFFAOYSA-N 3-trifluoromethylbenzoic acid Chemical group OC(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-N 0.000 description 2
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- FKNFZUFGHNFEHS-UHFFFAOYSA-N n-[5-(4-amino-2-cyanophenoxy)-2-fluorophenyl]-2,2,2-trifluoroacetamide Chemical compound N#CC1=CC(N)=CC=C1OC1=CC=C(F)C(NC(=O)C(F)(F)F)=C1 FKNFZUFGHNFEHS-UHFFFAOYSA-N 0.000 description 2
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- CLOXAWYNXXEWBT-UHFFFAOYSA-N tert-butyl n-(3-oxocyclopentyl)carbamate Chemical group CC(C)(C)OC(=O)NC1CCC(=O)C1 CLOXAWYNXXEWBT-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JASTZOAHAWBRLM-UHFFFAOYSA-N 1-(3-isocyanatophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(N=C=O)=C1 JASTZOAHAWBRLM-UHFFFAOYSA-N 0.000 description 1
- VQVBCZQTXSHJGF-UHFFFAOYSA-N 1-bromo-3-isocyanatobenzene Chemical compound BrC1=CC=CC(N=C=O)=C1 VQVBCZQTXSHJGF-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- SXJYSIBLFGQAND-UHFFFAOYSA-N 1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=O)=C1 SXJYSIBLFGQAND-UHFFFAOYSA-N 0.000 description 1
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 1
- CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 1
- LGPKFIGMLPDYEA-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(N=C=O)C=C1 LGPKFIGMLPDYEA-UHFFFAOYSA-N 0.000 description 1
- GFEPANUKFYVALF-UHFFFAOYSA-N 1-isothiocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=S)=C1 GFEPANUKFYVALF-UHFFFAOYSA-N 0.000 description 1
- NAIPEFIYIQFVFC-UHFFFAOYSA-N 2-(1-methylindol-3-yl)acetic acid Chemical compound C1=CC=C2N(C)C=C(CC(O)=O)C2=C1 NAIPEFIYIQFVFC-UHFFFAOYSA-N 0.000 description 1
- YLACBMHBZVYOAP-UHFFFAOYSA-N 2-fluoro-5-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(F)C(C#N)=C1 YLACBMHBZVYOAP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- SADHVOSOZBAAGL-UHFFFAOYSA-N 3-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)(F)F)=C1 SADHVOSOZBAAGL-UHFFFAOYSA-N 0.000 description 1
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- QCJPGIFKFKZXAQ-UHFFFAOYSA-N 4-(3-fluoroazetidin-1-yl)piperidine Chemical compound C1C(F)CN1C1CCNCC1 QCJPGIFKFKZXAQ-UHFFFAOYSA-N 0.000 description 1
- NFYYDQMFURPHCC-UHFFFAOYSA-N 6-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC=CC(C(F)(F)F)=N1 NFYYDQMFURPHCC-UHFFFAOYSA-N 0.000 description 1
- 102000040717 Alpha family Human genes 0.000 description 1
- 108091071248 Alpha family Proteins 0.000 description 1
- 101100034357 Arabidopsis thaliana RIPK gene Proteins 0.000 description 1
- 101100306081 Arabidopsis thaliana RPK1 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101100287598 Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) PKAR gene Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000003749 KINOMEscan Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 101100238379 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MPS1 gene Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UPXGGIRFDZENRD-UHFFFAOYSA-N ethyl 3-isocyanatobenzoate Chemical compound CCOC(=O)C1=CC=CC(N=C=O)=C1 UPXGGIRFDZENRD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- ALYAXIZITFKEAG-UHFFFAOYSA-N n-[5-(2-cyano-4-nitrophenoxy)-2-fluorophenyl]-2,2,2-trifluoroacetamide Chemical compound N#CC1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(F)C(NC(=O)C(F)(F)F)=C1 ALYAXIZITFKEAG-UHFFFAOYSA-N 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- RYGUCYSSMOFTSH-UHFFFAOYSA-N oxane-4-carbonyl chloride Chemical compound ClC(=O)C1CCOCC1 RYGUCYSSMOFTSH-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 229940081310 piperonal Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了一种苯并噻唑类衍生物或其异构体、盐或溶剂合物的前体药物，如通式I所示：各取代基定义见说明书。本发明的苯并噻唑类衍生物或其异构体、盐或溶剂合物的前体药物可以作为RIPK1和RIPK3激酶抑制剂，还可以作为程序性细胞坏死抑制剂，有效地抑制细胞坏死；可以用于制备程序性细胞坏死相关疾病的防治药物，或制备由RIPK1和RIPK3激酶紊乱、过度激活或过度相互作用引起的炎症性、感染性、缺血性或退行性相关疾病或组织损伤的药物。The invention discloses a prodrug of a benzothiazole derivative or its isomer, salt or solvate, as shown in general formula I: The definition of each substituent is shown in the specification. The prodrugs of benzothiazole derivatives or isomers, salts or solvates of the present invention can be used as RIPK1 and RIPK3 kinase inhibitors, and can also be used as programmed cell necrosis inhibitors, effectively inhibiting cell necrosis; It is used to prepare a drug for the prevention and treatment of programmed cell necrosis-related diseases, or to prepare a drug for inflammatory, infectious, ischemic or degenerative related diseases or tissue damage caused by RIPK1 and RIPK3 kinase disorder, over-activation or over-interaction.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a benzothiazole derivative and application thereof as a programmed cell necrosis inhibitor.
Background
Apoptosis is a Caspase-independent mode of cell death mediated by death receptors. When apoptosis is blocked, receptors of TNF- α and TNF- α family, Toll-like receptors 3 and 4, and interferon-alpha receptors, are capable of inducing apoptosis in cells when activated by corresponding ligands.
Research shows that protein kinases RIPK1 and RIPK3 form a complex and activate MLKL protein, and MLKL is polymerized to be directly positioned on a cell membrane and cause the cell membrane to break, so that the key mechanism for inducing programmed cell necrosis is realized. Programmed cell necrosis, due to the release of cellular contents, causes infiltration of a large number of inflammatory cells in the body to induce a severe inflammatory response. The disorder, overactivation or overactive interaction of RIPK1/RIPK3 kinase has a close correlation with various diseases, for example, the literature (Neotrophosis is active in childrens with inflammation bone diseases and conditions to inflammation in inflammation. am J gastroenterol.2014 Feb; 109(2):279-87.) reports that RIPK1/RIPK3 kinase-mediated necrosis is related to inflammatory bowel disease; the literature (necrosis Is an infectious Therapeutic Target in Experimental Therapeutic patent. cell Mol gastric hepatol Hepatol.2016 Jul; 2(4): 519) 535.) reports a correlation between necrosis and acute pancreatitis; the literature (Type I interference inductors in macrophages along with Salmonella enterica serovar. Nat Immunol.2012 Oct; 13(10):954-62.) reports that necrosis is associated with Salmonella infection; the literature (Liver-responsive pathological necrosis with type 1 microbial infection and type-2-mediated tissue repair reduction bacterial infection. immunity.2015 Jan 20; 42(1):145-58.) reports that necrosis is associated with Listeria infection; necrosis has been reported in the literature to be associated with Vaccinia virus infection (Vaccinium viruses induced by microorganisms in the tissue by A STAT3-dependent mechanism. PLoS one.2014 Nov 24; 9(11): e 113690); the literature (CaMKII a RIP3 substrate formatting iso-and oxidative stress-induced myogenic Necrtopsis. Nat Med.2016Feb; 22(2):175-82.) reports that necrosis is associated with ischemic cardiomyopathy; the literature (Chemical inhibitor of non-porous cell death with thermal biological potential for isochemical brain in therapy. Natchem biol.2005 Jul; 1(2):112-9.) reports that necrosis is associated with ischemic stroke; the literature (neuropathies activation in Alzheimer's disease. Nat Neurosci.2017 Sep; 20(9): 1236-; necrosis has been reported in the literature to be associated with atherosclerosis (Targeting pathological necrosis for therapeutic and diagnostic interventions in atherosclerosis. Sci adv.2016 Jul 22; 2(7): e 1600224.).
Therefore, the identification and discovery of the inhibitor of programmed cell necrosis are of great significance for the clinical treatment of diseases related to programmed cell necrosis.
Disclosure of Invention
The first purpose of the invention is to provide a benzothiazole derivative.
The second purpose of the invention is to provide the application of the benzothiazole derivative serving as RIPK1 and RIPK3 kinase inhibitors.
The third purpose of the invention is to provide the application of the benzothiazole derivative as the programmed cell necrosis inhibitor.
The fourth purpose of the invention is to provide the application of the benzothiazole derivative in preparing a medicine for preventing and treating programmed cell necrosis related diseases or preparing a medicine for treating inflammatory, infectious, ischemic or degenerative related diseases or tissue injury caused by RIPK1 and RIPK3 kinase disorder, over-activation or over-interaction.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the present invention provides a prodrug of a benzothiazole derivative or its isomer, salt or solvate, represented by formula I:
wherein R is1Is alkyl, amino, hydroxy, -NR5CO-W1、-NR5CO-W1-O-W2、-NR5CO-W1-SH、-NR5CO-W1-NR6、-NR5COOR6、NR5CO-CO-、-NR5CONR6、-NR5CONR6-W1、-CONR5；R5、R6Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; w1、W2Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R2、R3each independently selected from hydrogen, halogen, amino, nitro, hydroxy, cyano, alkyl, alkoxy, alkylamino, aminoalkyl, acyl, amido, thioalkyl, trifluoromethyl, trifluoromethoxy, carboxy, alkoxycarbonyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, saturated or unsaturated heterocycle;
R4is R7CO-、-R7CO-W3、-R7CO-W3-R8、R7CO-W3-O-、-R7CO-W3-O-W4、-R7CO-W3-NR8、R7CO-CO-、R7CONR8-、R7CONR8-W3-、R7CONR8-W3-O-、-CONR8、-SO2R7、-R7-W3、R7CS-、-R7CS-W3、-R7CS-W3-R8、R7CS-W3-O-、-R7CS-W3-O-W4、R7CS-W3-S-、R7CS-W3-NR8-、R7CS-CS-、R7CSNR8-、R7CSNR8-W3-、R7CSNR8-W3-O-or-CSNR8；
R7、R8Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; w3、W4Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
x is oxygen, sulfur or imino (-NH-);
y is oxygen, sulfur or imino (-NH-);
z is oxygen,
Or an imino group (-NH-).
Preferably, in the formula I, X is sulfur; y is oxygen; z is imino (-NH-) or
More preferably, in formula I, R1is-NR5CO-W1、-NR5CO-W1-O-W2、-NR5CO-W1-SH、-NR5CO-W1-NR6、-NR5COOR6、NR5CO-CO-、-NR5CONR6、-NR5CONR6-W1、-CONR5；
R5、R6Each independently is hydrogen;
W1、W2each independentlySelected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
R2、R3each independently selected from hydrogen, halogen, amino, nitro, hydroxy, cyano, alkyl, alkoxy, alkylamino, aminoalkyl, acyl, amido, thioalkyl, trifluoromethyl, trifluoromethoxy, carboxy, alkoxycarbonyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, saturated or unsaturated heterocycle;
R4is R7CO-、-R7CO-W3、-R7CO-W3-R8、R7CO-W3-O-、-R7CO-W3-O-W4、-R7CO-W3-NR8、R7CO-CO-、R7CONR8-、R7CONR8-W3-、R7CONR8-W3-O-、-CONR8、-SO2R7、-R7-W3、R7CS-、-R7CS-W3、-R7CS-W3-R8、R7CS-W3-O-、-R7CS-W3-O-W4、R7CS-W3-S-、R7CS-W3-NR8-、R7CS-CS-、R7CSNR8-、R7CSNR8-W3-、R7CSNR8-W3-O-or-CSNR8；
R7、R8Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; w3、W4Each independently selected from hydrogen, saturated or unsaturated chain alkyl, cycloalkyl, saturated or unsaturated heterocycle, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;
x is sulfur;
y is oxygen;
z is imino (-NH-)) or
In the above general structure, each substituent is not selected from the following combinations: r1is-NR5CO-W1、R2Is 7-cyano, R3Is 4-fluoro, R4Is R7CO-, Z is imino (-NH-), W1Is cyclopropyl, R5Is hydrogen, R7Is 3-trifluoromethyl benzyl, X is sulfur, Y is oxygen, the compound is TAK-632, and the chemical structural formula is as follows:
most preferably, the benzothiazole derivatives are selected from one of the following structures:
benzyl (7-cyano-6- (4-fluoro-3- (2,2, 2-trifluoroacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) carbamate;
allyl (7-cyano-6- (4-fluoro-3- (2,2, 2-trifluoroacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) carbamate;
benzyl (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) carbamate;
n- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) nonanamide;
n- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) propanamide;
n- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) benzamide;
n- (7-cyano-6- (4-fluoro-3- (2- (4-nitrophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (7-cyano-6- (4-fluoro-3- (2-phenylacetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (5- ((7-cyano-2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -3- (trifluoromethyl) benzamide;
n- (7-cyano-6- (4-fluoro-3- (2- (3-fluorophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (7-cyano-6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (3, 5-bis (trifluoromethyl) phenyl) acetamido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3-nitrophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclohexanecarboxamide;
n- (6- (4-fluoro-3- (2- (2- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (m-tolyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) propionylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (pyridin-2-yl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (4-fluoro-3 (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (2-chloro-3- (trifluoromethyl) phenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3-methoxyphenyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethoxy) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (benzo [ d ] [1,3] dioxol-5-yl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (6- (trifluoromethyl) pyridin-2-yl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (5- ((2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -1- (3- (trifluoromethyl) phenyl) cyclopropane-1-carboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclobutanecarboxamide;
n- (6- (4-fluoro-3- (2- (1-methyl-1H-indol-3-yl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopentanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) isobutyramide;
n- (6- (3- (2- (3-cyanophenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (3, 4-dimethylphenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) tetrahydro-2H-pyran-4-carboxamide;
n- (6- (4-fluoro-3- (2- (3-hydroxyphenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (4- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3-methoxyphenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (m-tolyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
ethyl 3- (3- (5- ((2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) ureido) benzoate;
n- (6- (3- (3- (3-acetylphenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (3- (3-bromophenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) thioureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (6- (trifluoromethyl) pyridin-2-yl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- ((3- (trifluoromethyl) benzyl) amino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- ((benzo [ d ] [1,3] dioxol-5-ylmethyl) amino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- ((3- (trifluoromethyl) phenyl) sulfonamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide.
The second aspect of the invention provides an application of a benzothiazole derivative shown in the general formula I or a prodrug of an isomer, a salt or a solvate thereof as an RIPK1 or RIPK3 kinase inhibitor.
The third aspect of the invention provides an application of a benzothiazole derivative shown in the general formula I or a prodrug of an isomer, a salt or a solvate thereof as a programmed cell necrosis inhibitor.
The fourth aspect of the invention provides an application of a benzothiazole derivative shown in the general formula I or a prodrug of an isomer, a salt or a solvate thereof in preparing a medicine for preventing and treating programmed cell necrosis related diseases or preparing a medicine for treating inflammatory, infectious, ischemic or degenerative related diseases or tissue injury caused by RIPK1 or RIPK3 kinase disorder, over-activation or over-interaction.
The inflammatory, infectious, ischemic or degenerative related diseases or tissue damage is mediated by RIPK1/RIPK3 kinase, or is initiated by programmed cell necrosis.
The inflammatory, infectious, ischemic or degenerative related diseases are selected from: systemic inflammatory syndrome, acetaminophen-induced liver injury, acute pancreatitis, inflammatory bowel disease, sepsis, salmonella infection, listeria infection, vaccinia virus infection, alzheimer's disease, ischemic cardiomyopathy, ischemic stroke, atherosclerosis.
The tissue damage comprises: liver damage, hepatotoxicity or hepatocyte necrosis.
The fifth aspect of the invention also provides a pharmaceutical composition, which comprises a precursor drug of the benzothiazole derivative shown in the general formula I or an isomer, a salt or a solvate thereof and a pharmaceutically acceptable auxiliary material.
The salt is a salt formed by reacting a compound with an inorganic acid, an organic acid, an alkali metal, an alkaline earth metal or the like. These salts include (but are not limited to): (1) salts with the following inorganic acids: such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, diphosphoric acid, hydrobromic acid; (2) salts with organic acids such as acetic acid, lactic acid, succinic acid, p-toluenesulfonic acid, salicylic acid, oxalic acid, succinic acid, tartaric acid, methanesulfonic acid, maleic acid, fumaric acid or arginine. Other salts include those formed with alkali or alkaline earth metals (e.g., sodium, potassium, calcium or magnesium), in the form of esters, carbamates, or other conventional "prodrugs". The compounds have one or more asymmetric centers. Thus, these compounds may exist as racemic mixtures, individual enantiomers, individual diastereomers, mixtures of diastereomers, cis or trans isomers. The term "precursor of a compound" refers to a compound which, when administered by a suitable method, undergoes a metabolic or chemical reaction in the patient to convert the precursor to a compound of formula (I), or a salt or solution of a compound of formula (I).
The dosage form of the pharmaceutical composition of the present invention may be various, as long as it is a dosage form that enables the active ingredient to efficiently reach the body of a mammal. Such as may be selected from: a solution, suspension, tablet, capsule, powder, granule, or syrup. Depending on the type of disease to be treated by the compounds of the present invention, one skilled in the art may select a dosage form that is convenient to use.
The terms: the term "isomer" as used herein includes: geometric isomers, enantiomers, diastereomers (e.g., cis-trans isomers, conformational isomers); the term "solvate" as used herein means a compound carrying a solvent molecule, e.g., the solvate may be a hydrate; in the present invention, the term "comprising" means that various ingredients can be used together in the mixture or composition of the present invention. Thus, the terms "consisting essentially of and" consisting of are encompassed by the term "comprising"; in the present invention, a "pharmaceutically acceptable" ingredient is one that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio; in the present invention, the "pharmaceutically acceptable carrier" is a pharmaceutically or food acceptable solvent, suspending agent or excipient for delivering the compound of formula (I), isomer, solvate, precursor, or pharmaceutically acceptable salt thereof of the present invention to animals or humans. The carrier may be a liquid or a solid.
Due to the adoption of the technical scheme, the invention has the following advantages and beneficial effects:
the benzothiazole derivative or the isomer, the salt or the solvate of the benzothiazole derivative can be used as an RIPK1 and RIPK3 kinase inhibitor and can also be used as a programmed cell necrosis inhibitor to effectively inhibit cell necrosis; can be used for preparing medicaments for preventing and treating diseases related to programmed cell necrosis, or preparing medicaments for treating inflammatory, infectious, ischemic or degenerative related diseases or tissue injury caused by disorder, over-activation or over-interaction of RIPK1 and RIPK3 kinases.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. All raw materials without the synthesis method are purchased from manufacturers such as exploration platforms, Aladdin, Sigma-Aldrich and the like, and are all analytically pure.
Example 1
Benzyl (7-cyano-6- (4-fluoro-3- (2,2, 2-trifluoroacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) carbamate
The synthetic route is as follows:
step a: synthesis of 2- (3-amino-4-fluorophenoxy) -5-nitrobenzonitrile.
To a solution of 3-amino-4-fluorophenol (3g, 22.42mmol) and 2-fluoro-5-nitrobenzonitrile (4.19g, 24.66mmol) in DMF (20mL) at room temperature was added K2CO3(4.89g, 35.4 mmol). The solution was stirred at 80 ℃ for 8h, and the solution was extracted with ethyl acetate, washed with saturated sodium chloride and dried over anhydrous sodium sulfate, insoluble material was filtered off, filtered and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 5: 1-4: 1), and the obtained solution was concentrated under reduced pressure to give 1.95g of a pale yellow solid with a yield of 35%.
Step b: synthesis of N- (5- (2-cyano-4-nitrophenoxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide.
To a solution of 2- (3-amino-4-fluorophenoxy) -5-nitrobenzonitrile (1.95g, 7.14mmol) in THF (30mL) at 0 deg.C was added trifluoroacetic anhydride (1.21mL, 8.56mmol), and the solution was stirred at room temperature for 1.5 h. The reaction mixture was diluted with ethyl acetate, washed successively with water, an aqueous sodium bicarbonate solution and saturated sodium chloride, and dried over anhydrous sodium sulfate, insoluble materials were filtered off, the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 5: 1-4: 1), and the obtained solution was concentrated under reduced pressure to obtain 2.38g of a pale yellow solid, yield 90%.
Step c: synthesis of N- (5- (4-amino-2-cyanophenoxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide.
To N- (5- (2-cyano-4-nitrophenoxy) -2-fluorophenyl) -2,2, 2-trifluoroacetyl (2.38g, 6.45mmol) in EtOH/H2To a solution (50mL) of O (5:1) was added ammonium chloride (1.72g, 32.23mmol), then to the solution was added iron powder (1.8g, 32.23mmol), and the solution was stirred at 0 ℃ for 30min, after which the reaction was heated to 55 ℃ for 2 h. Insoluble material was then filtered off over celite, the residue was collected and the mixture was adjusted to pH 8 with sodium bicarbonate solution. The reaction mixture was diluted with DCM, dried over anhydrous sodium sulfate, the insoluble material filtered off, filtered and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 4: 1-3: 1), and the obtained solution was concentrated under reduced pressure to obtain 1.08g of a white solid with a yield of 49%.
Step d: synthesis of N- (5- ((2-amino-7-cyanobenzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide.
Potassium thiocyanate (1.104g, 11.37mmol) was suspended in acetic acid (10mL) and the solution was stirred at room temperature for 10 min. A solution of N- (5- (4-amino-2-cyanophenoxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (950mg, 2.84mmol) in acetic acid (10mL) was added to the suspension, and the mixture was further stirred at room temperature for 10min, a solution of bromine (676mg, 4.26mmol) in acetic acid (5mL) was added to the mixture, and the mixture was stirred at room temperature for 3h, the resulting yellow insoluble matter was filtered off and washed with acetic acid, the filtrate and the washing solution were combined, and the mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed successively with water, a sodium bicarbonate solution and a saturated saline solution, and dried over anhydrous sodium sulfate, the insoluble matter was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 2: 1-1: 1), and the resulting solution was concentrated under reduced pressure to give 1.05g of a white solid in a yield of 95%.
Step e: synthesis of benzyl (7-cyano-6- (4-fluoro-3- (2,2, 2-trifluoroacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) carbamate.
N- (5- ((2-amino-7-cyanobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (500mg, 1.26mmol) was dissolved in pyridine (10mL), benzyl chloride (428mg, 2.52mmol) was added slowly under nitrogen atmosphere, stirred at room temperature overnight, the reaction solution was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 200mg of a white solid in 30% yield.1H NMR(300MHz,DMSO-d6)δ12.56(s,1H),11.38(s,1H),8.01(d,1H,J＝9Hz),7.34-7.49(m,7H),7.21-7.25(m,1H),7.13(d,1H,J＝9Hz),5.31(s,2H)；MS(ESI):m/z[M+H]+:531.48.
Example 2
Allyl (7-cyano-6- (4-fluoro-3- (2,2, 2-trifluoroacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) carbamate
Preparation of reference example 1 with N- (5- ((2-amino-7-cyanobenzo [ d)]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (500mg, 1.26mmol) was dissolved in pyridine (10mL), allyl chloroformate (303mg, 2.52mmol) was slowly added under a nitrogen atmosphere, the mixture was stirred at room temperature overnight, the reaction solution was directly evaporated to dryness, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to yield 250mg of a white solid in 41% yield.1H NMR(300MHz,DMSO-d6)δ12.55(s,1H),11.39(s,1H),8.01(d,1H,J＝9Hz),7.46(t,1H,J＝9.6Hz),7.35-7.36(m,1H),7.21-7.24(m,1H),7.13(d,1H,J＝9Hz),5.95-6.06(m,1H),5.28-5.45(m,2H),4.76(d,2H,J＝4.8Hz)；MS(ESI):m/z[M+H]+:481.33.
Example 3
Benzyl (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) carbamate
The synthetic route is as follows:
step f: synthesis of benzyl (6- (3-amino-4-fluorophenoxy) -7-cyanobenzo [ d ] thiazol-2-yl) carbamate.
To a solution of sodium borohydride (280mg, 7.4mmol) in ethanol (10mL) was added methanol (0.5mL) and the product of example 1 (196mg, 0.37mmol) was added to the suspension at 0 deg.C. The reaction mixture was stirred at 0 ℃ for 0.5h, then at room temperature for 0.5h, the mixture was diluted with ethyl acetate (20mL), and the resulting mixture was filtered to concentrate the mixture in vacuo, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble material, dried under reduced pressure, and purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 2: 1-1: 1) to give 150mg of a pale yellow solid in 94% yield, which was directly subjected to the next reaction without purification.
Step g synthesis of benzyl (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) carbamate.
The compound benzyl (6- (3-amino-4-fluorophenoxy) -7-cyanobenzo [ d]Thiazol-2-yl) carbamate (40mg, 0.09mmol) and 2- (3- (trifluoromethyl) phenyl) acetic acid (20mg, 0.11mmol) were dissolved in pyridine (5mL), 2- (7-oxybenzotriazole) -N, N' -tetramethyluronium Hexafluorophosphate (HATU) (68mg, 0.18mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered through insoluble sodium sulfateThe residue was dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), and recrystallized from ethyl acetate and petroleum ether to give 33mg of a white solid in a yield of 59%.1H NMR(300MHz,DMSO-d6)δ12.54(s,1H),10.22(s,1H),7.83-7.97(m,2H),7.57-7.68(m,4H),7.37-7.46(m,6H),6.98-7.07(m,2H),5.30(s,2H),3.88(s,2H)；MS(ESI):m/z[M+H]+:621.39.
Example 4
N- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) nonanamide
N- (5- ((2-amino-7-cyanobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (300mg, 0.76mmol) was dissolved in pyridine (10mL), nonanoyl chloride (267mg, 1.51mmol) was added slowly under nitrogen, the reaction was stirred at room temperature overnight, the reaction was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to yield 150mg of a white solid in 31% yield. The last two steps of preparation refer to step f and step g in example 3,1H NMR(300MHz,DMSO-d6)δ12.66(s,1H),10.23(s,1H),7.98(d,1H,J＝9Hz),7.82-7.85(m,1H),7.68(s,1H),7.52-7.62(m,3H),7.38(t,1H,J＝9.3Hz),7.06(d,1H,J＝9Hz),6.94-6.99(m,1H),3.88(s,2H),2.50-2.53(m,2H),1.60-1.62(m,2H),1.25-1.27(m,10H),0.83-0.87(m,3H)；MS(ESI):m/z[M+H]+:637.40.
example 5
N- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) propanamide
N- (5- ((2-amino-7-cyanobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluoroPhenyl) -2,2, 2-trifluoroacetamide (300mg, 0.76mmol) was dissolved in pyridine (10mL), propionyl chloride (140mg, 1.51mmol) was slowly added under a nitrogen atmosphere, stirred at room temperature overnight, the reaction solution was directly evaporated to dryness, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to yield 160mg of a white solid in 39% yield. The last two steps of preparation refer to step f and step g in example 3,1H NMR(600MHz,DMSO-d6)δ12.62(s,1H),10.22(s,1H),7.97(d,1H,J＝9Hz),7.82-7.86(m,1H),7.68(s,1H),7.60-7.61(m,2H),7.53-7.56(m,1H),7.37(t,1H,J＝9.6Hz),7.06(d,1H,J＝8.4Hz),6.96-6.97(m,1H),3.88(s,2H),2.54(q,2H,J＝7.2Hz),1.12(t,3H,J＝7.8Hz)；MS(ESI):m/z[M+H]+:543.0.
example 6
N- (7-cyano-6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) benzamide
N- (5- ((2-amino-7-cyanobenzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (300mg, 0.76mmol) was dissolved in pyridine (10mL), benzoyl chloride (212mg, 1.51mmol) was slowly added under a nitrogen atmosphere, the mixture was stirred at room temperature overnight, the reaction solution was directly evaporated to dryness, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 3: 1-2: 1) to give 154mg of a white solid in a yield of 41%.
The last two steps of preparation refer to step f and step g in example 3,1H NMR(300MHz,DMSO-d6)δ12.21(s,1H),10.25(s,1H),8.13(d,2H,J＝6.9Hz),8.02(d,1H,J＝8.7Hz),7.87(s,1H),7.57-7.68(m,7H),7.38(t,1H,J＝9.3Hz),6.99-7.11(m,2H),3.89(s,2H)；MS(ESI):m/z[M+H]+:590.9.
example 7
N- (7-cyano-6- (4-fluoro-3- (2- (4-nitrophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
N- (5- ((2-amino-7-cyanobenzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (526mg, 1.41mmol) was dissolved in pyridine (15mL), cyclopropanecarbonyl chloride (296mg, 2.83mmol) was slowly added under a nitrogen atmosphere, the mixture was stirred at room temperature overnight, the reaction mixture was directly evaporated to dryness, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 3: 1-2: 1) to give 515mg of white solid in 78% yield.
Preparation reference example 3 to a solution of sodium borohydride (636mg, 16.8mmol) in ethanol (20mL) was added methanol (1mL) and the product of the previous step (390mg, 0.84mmol) was added to the suspension at 0 ℃. The reaction mixture was stirred at 0 ℃ for 0.5h, then at room temperature for 0.5h, the mixture was diluted with ethyl acetate (20mL), and the resulting mixture was filtered, concentrated in vacuo, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble material, dried under reduced pressure, and purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 2: 1-1: 1) to give 300mg of a pale yellow solid in 97% yield, which was directly subjected to the next reaction without purification.
The product of the previous step (30mg, 0.08mmol) and p-nitrophenylacetic acid (18mg, 0.097mmol) were dissolved in pyridine (5mL), 2- (7-benzotriazole oxide) -N, N' -tetramethylurea hexafluorophosphate (61mg, 0.16mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), recrystallized with ethyl acetate and petroleum ether to give 33mg of a white solid with a yield of 70%.1H NMR(300MHz,DMSO-d6)δ12.98(s,1H),10.27(s,1H),8.18(d,2H,J＝8.4Hz),7.95-8.00(m,1H),7.83-7.84(m,1H),7.58(d,2H,J＝8.4Hz),7.37(t,1H,J＝9.9Hz),7.07(d,1H,J＝9Hz),6.95-6.98(m,1H),3.94(s,2H),1.98-2.04(m,1H),0.99-1.01(m,4H)；MS(ESI):m/z[M+H]+:532.0.
Example 8
N- (7-cyano-6- (4-fluoro-3- (2-phenylacetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 7 was prepared by replacing p-nitroacetophenone in the last step with phenylacetic acid, dissolving phenylacetic acid (13mg, 0.097mmol) and the product of the previous step (30mg, 0.08mmol) in pyridine (5mL), adding 2- (7-benzotriazol oxide) -N, N' -tetramethylurea hexafluorophosphate (61mg, 0.16mmol) to the solution at room temperature, stirring the mixture at 80 ℃ for 3h, concentrating the reaction mixture under reduced pressure, extracting with ethyl acetate, washing with saturated sodium chloride, drying over anhydrous sodium sulfate, filtering off insoluble matter, drying under reduced pressure, purifying with silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), recrystallizing with ethyl acetate and petroleum ether to give a white solid 20mg, yield 53%.1H NMR(300MHz,DMSO-d6)δ12.99(s,1H),10.15(s,1H),7.98(d,1H,J＝9Hz),7.84-7.87(m,1H),7.30-7.39(m,6H),7.06(d,1H,J＝9Hz),6.94-6.98(m,1H),1.98-2.01(m,1H),0.99-1.02(m,4H)；MS(ESI):m/z[M+H]+:487.0.
Example 9
N- (5- ((7-cyano-2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -3- (trifluoromethyl) benzamide
Preparation of reference example 7, p-nitroacetoacetate in the last step was replaced with 3-trifluoromethylbenzoic acid, 3-trifluoromethylbenzoic acid (18mg, 0.097mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (5mL), and the solution was added thereto at room temperatureTo the solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (61mg, 0.16mmol), the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 20mg of white solid in 50% yield.1H NMR(300MHz,DMSO-d6)δ12.99(s,1H),10.50(s,1H),8.23-8.28(m,2H),7.97-8.06(m,2H),7.78(t,1H,J＝7.8Hz),7.50-7.53(m,1H),7.43(t,1H,J＝9.6Hz),7.11-7.18(m,2H),1.99-2.04(m,1H),0.99-1.02(m,4H)；MS(ESI):m/z[M+H]+:541.0.
Example 10
N- (7-cyano-6- (4-fluoro-3- (2- (3-fluorophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 7, p-nitrophenylacetic acid in the last step was replaced with 3-fluorophenylacetic acid, 3-fluorophenylacetic acid (15mg, 0.097mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (5mL), 2- (7-benzotriazole oxide) -N, N' -tetramethylurea hexafluorophosphate (61mg, 0.16mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, and purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized from ethyl acetate and petroleum ether to give 22mg of a white solid in 55% yield. ,1H NMR(300MHz,DMSO-d6)δ12.99(s,1H),10.18(s,1H),7.99(d,1H,J＝9Hz),7.83-7.86(m,1H),7.31-7.40(m,2H),7.04-7.15(m,4H),6.95-6.99(m,1H),3.78(s,2H),1.98-2.04(m,1H),0.99-1.02(m,4H)；MS(ESI):m/z[M+H]+:505.0.
example 11
N- (7-cyano-6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 7, p-nitroacetophenone in the last step was replaced with 2-fluoro-3- (trifluoromethyl) phenylacetic acid, 2-fluoro-3- (trifluoromethyl) phenylacetic acid (29mg, 0.13mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (5mL), 2- (7-benzotriazol oxide) -N, N' -tetramethylurea hexafluorophosphate (83mg, 0.22mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble substances, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether, 33mg of a white solid was obtained in 55% yield.1H NMR(300MHz,DMSO-d6)δ12.95(s,1H),10.28(s,1H),7.98(d,1H,J＝9Hz),7.82-7.85(m,1H),7.65-7.74(m,2H),7.34-7.41(m,2H),7.08(d,1H,J＝9Hz),6.95-7.00(m,1H),3.96(s,2H),1.98-2.03(m,1H),0.98-1.01(m,4H)；HRMS(ESI,positive)m/z calcd for C27H17F5N4O3S[M+H]+:573.1014；found 573.1024.
Example 12
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 1 to a solution of 3-amino-4-fluorophenol (3g, 23.6mmol) and 1-fluoro-4-nitrobenzene (3.6g, 25.9mmol) in DMF (30mL) at room temperature was added K2CO3(4.89g, 35.4 mmol). The solution was stirred at 80 ℃ for 8h, and the solution was extracted with ethyl acetate, washed with saturated sodium chloride and dried over anhydrous sodium sulfateThe insoluble matter was filtered off, filtered and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 5: 1-4: 1), and the obtained solution was concentrated under reduced pressure to obtain 4.3g of a pale yellow solid in a yield of 74%.
The latter three steps are carried out with reference to example 1, the fourth step is followed by the reaction preparation reference example 7, p-nitrophenylacetic acid in the last step is replaced by 3-trifluoromethylphenylacetic acid, 3-trifluoromethylphenylacetic acid (101mg, 0.41mmol) and the product of the previous step (30mg, 0.08mmol) are dissolved in pyridine (10mL), 2- (7-benzotriazol oxide) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (259mg, 0.68mmol) is added to the solution at room temperature, the mixture is stirred at 80 ℃ for 3h, the reaction mixture is concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), recrystallized with ethyl acetate and petroleum ether, 100mg of a white solid was obtained in 56% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),10.11(s,1H),7.67-7.72(m,3H),7.63(d,1H,J＝2.4Hz),7.59-7.61(m,2H),7.53-7.56(m,1H),7.26-7.29(m,1H),7.10(dd,1H,J＝2.4,8.4Hz),6.78-6.81(m,1H),3.86(s,2H),1.98-2.00(m,1H),0.93-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C26H19F4N3O3S[M+H]+:530.1156；found 530.1169.
Example 13
N- (6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 2-fluoro-3- (trifluoromethyl) phenylacetic acid, 2-fluoro-3- (trifluoromethyl) phenylacetic acid (35mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), and 2- (7-benzotriazol oxide) was added to the solution at room temperature-N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol), the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, the insoluble material was filtered, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), and recrystallized from ethyl acetate and petroleum ether to give 25mg of a white solid in 38% yield.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),10.17(s,1H),7.66-7.72(m,4H),7.63(d,1H,J＝3Hz),7.37(t,1H,J＝7.8Hz),7.27-7.31(m,1H),7.09(dd,1H,J＝2.4,9Hz),6.79-6.82(m,1H),3.93(s,2H),1.98-2.01(m,1H),0.92-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C26H18F5N3O3S[M+H]+:548.1056；found 548.1074.
Example 14
N- (6- (3- (2- (3, 5-bis (trifluoromethyl) phenyl) acetamido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3, 5-bistrifluoromethylphenylacetic acid, 3, 5-bistrifluoromethylphenylacetic acid (38mg, 0.14mmol) and the product of the last step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-oxybenzotriazole) -N, N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether to give 32mg of a white solid, the yield thereof was found to be 46%.1H NMR(600MHz,DMSO-d6)δ12.59(s,1H),10.15(s,1H),8.01(s,2H),7.98(s,1H),7.71(d,1H,J＝9Hz),7.65-7.67(m,1H),7.62(d,1H,J＝2.4Hz),7.27-7.30(m,1H),7.09(dd,1H,J＝2.4,8.4Hz),6.79-6.82(m,1H),3.31(s,2H),1.98-2.01(m,1H),0.93-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C27H18F7N3O3S[M+H]+:598.1024；found 598.1032.
Example 15
N- (6- (4-fluoro-3- (2- (3-nitrophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3-nitrophenylacetic acid, 3-nitrophenylacetic acid (25mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), to the solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 20mg of a white solid in 33% yield.1H NMR(600MHz,DMSO-d6)δ12.59(s,1H),10.14(s,1H),8.20(s,1H),8.09-8.11(m,1H),7.74-7.76(m,1H),7.70-7.71(m,2H),7.59-7.62(m,2H),7.28(t,1H,J＝10.2Hz),7.09(dd,1H,J＝2.4,8.4Hz),6.78-6.80(m,1H),3.92(s,2H),1.98-2.01(m,1H),0.94-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C25H19FN4O5S[M+H]+:507.1127；found 507.1151.
Example 16
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclohexanecarboxamide
The previous four steps refer to example 12, the fifth step: n- (5- (2-aminobenzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (200mg, 0.53mmol) was dissolved in pyridine (10mL), cyclohexanecarboxyl chloride (155mg, 1.06mmol) was added slowly under a nitrogen atmosphere, stirred at room temperature overnight, the reaction was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 248mg of white solid in 75% yield.
Sixth step and seventh step preparation referring to example 12,1H NMR(600MHz,DMSO-d6)δ12.23(s,1H),10.11(s,1H),7.69-7.71(m,2H),7.67(s,1H),7.62(d,1H,J＝2.4Hz),7.59-7.60(m,2H),7.53-7.55(m,1H),7.28(t,1H,J＝10.2Hz),7.09(dd,1H,J＝2.4,9Hz),6.78-6.80(m,1H),3.86(s,2H),2.53-2.55(m,1H),1.27-1.44(m,10H)；HRMS(ESI,positive)m/z calcd for C29H25F4N3O3S[M+H]+:572.1602；found 572.1633.
example 17
N- (6- (4-fluoro-3- (2- (2- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 2-trifluoromethylphenylacetic acid, 2-trifluoromethylphenylacetic acid (34mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), to the solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 20mg of a white solid with a yield of 32%.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),10.10(s,1H),7.67-7.71(m,3H),7.63(d,1H,J＝2.4Hz),7.61(t,1H,J＝7.8Hz),7.44-7.49(m,2H),7.22(t,1H,J＝10.2Hz),7.10(dd,1H,J＝2.4,8.4Hz),6.78-6.80(m,1H),4.00(s,2H),1.98-2.01(m,1H),0.94-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C26H19F4N3O3S[M+H]+:530.1156；found 530.1173.
Example 18
N- (6- (4-fluoro-3- (2- (m-tolyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3-methylphenylacetic acid, 3-methylphenylacetic acid (21mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), to the solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 21mg of a white solid with a yield of 38%.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),9.98(s,1H),7.70-7.72(m,2H),7.62(d,1H,J＝2.4Hz),7.24-7.28(m,1H),7.18(t,1H,J＝7.8Hz),7.08-7.11(m,3H),7.02(d,1H,J＝7.2Hz),6.77-6.79(m,1H),3.67(s,2H),2.26(s,3H),1.98-2.01(m,1H),0.94-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C26H22FN3O3S[M+H]+:476.1439；found 476.1449.
Example 19
N- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) propionylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid was replaced with 3-methylpropanoic acid in the last step, 3-methylpropanoic acid (30mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), to this solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 25mg of a white solid with a yield of 39%.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),9.79(s,1H),7.73(d,1H,J＝11.4Hz),7.66-7.67(m,1H),7.63(d,1H,J＝2.4Hz),7.59(s,1H),7.48-7.54(m,3H),7.23-7.26(m,1H),7.10(dd,1H,J＝2.4,8.4Hz),6.76-6.79(m,1H),2.96(t,2H,J＝8.4Hz),2.74(t,2H,J＝7.8Hz),1.98-2.01(m,1H),0.94-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C27H21F4N3O3S[M+H]+:544.1313；found 544.1324.
Example 20
N- (6- (4-fluoro-3- (2- (pyridin-2-yl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 2-pyridineacetic acid hydrochloride, 2-pyridineacetic acid hydrochloride (24mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-benzotriazol oxide) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, and anhydrous sulfurSodium acid was dried, the insoluble material was filtered, dried under reduced pressure, and purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), and recrystallized from ethyl acetate and petroleum ether to give 23mg of a white solid in a yield of 42%.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),10.21(s,1H),8.49(d,1H,J＝4.2Hz),7.70-7.76(m,3H),7.63(d,1H,J＝2.4Hz),7.36(d,1H,J＝7.8Hz),7.25-7.29(m,2H),7.10(dd,1H,J＝2.4,9Hz),6.77-6.80(m,1H),3.93(s,2H),1.98-2.01(m,1H),0.94-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C24H19FN4O3S[M+H]+:463.1325；found 463.1248.
Example 21
N- (6- (4-fluoro-3- (2- (4-fluoro-3 (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 4-fluoro-3-trifluoromethylphenylacetic acid, 4-fluoro-3-trifluoromethylphenylacetic acid (31mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-benzotriazol oxide) -N, N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble substances, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether, 26mg of a white solid was obtained in a yield of 40%.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),10.09(s,1H),7.65-7.72(m,4H),7.62(d,1H,J＝2.4Hz),7.43(t,1H,J＝9Hz),7.27(t,1H,J＝10.2Hz),7.09(dd,1H,J＝2.4,9Hz),6.78-6.81(m,1H),3.84(s,2H),1.98-2.01(m,1H),0.93-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C26H18F5N3O3S[M+H]+:548.1062；found 548.1069.
Example 22
N- (6- (3- (2- (2-chloro-3- (trifluoromethyl) phenyl) acetamido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 2-chloro-3-trifluoromethylphenylacetic acid, 2-chloro-3-trifluoromethylphenylacetic acid (33mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-benzotriazol oxide) -N, N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble substances, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether, 21mg of a white solid was obtained in 31% yield.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),10.19(s,1H),7.74(d,1H,J＝2.4Hz),7.70-7.72(m,3H),7.62(d,1H,J＝2.4Hz),7.50(t,1H,J＝7.8Hz),7.28(t,1H,J＝9Hz),7.10(dd,1H,J＝2.4,8.4Hz),6.78-6.81(m,1H),4.06(s,2H),1.98-2.01(m,1H),0.94-0.95(m,4H)；MS(ESI):m/z[M+H]+:563.9.
Example 23
N- (6- (4-fluoro-3- (2- (3-methoxyphenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3-methoxyphenylacetic acid, 3-methoxyphenylacetic acid (23mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), and 2- (7-oxybenzotriazole) -N, N, N ', N' -tetramethyluronhexakis were added to the solution at room temperatureFluorophosphate (91mg, 0.24mmol), the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, the insoluble material was filtered, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), and recrystallized with ethyl acetate and petroleum ether to give 30mg of white solid in 52% yield.1H NMR(300MHz,DMSO-d6)δ12.63(s,1H),10.02(s,1H),7.70-7.73(m,2H),7.64(d,1H,J＝2.4Hz),7.19-7.30(m,2H),7.10(dd,1H,J＝2.4,8.7Hz),6.86-6.88(m,2H),6.77-6.81(m,2H),3.72(s,3H),3.69(s,2H),1.99-2.01(m,1H),0.94-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C26H22FN3O4S[M+H]+:492.1388；found 492.1399.
Example 24
N- (6- (4-fluoro-3- (2- (3- (trifluoromethoxy) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3-trifluoromethylphenylacetic acid, 3-trifluoromethylphenylacetic acid (31mg, 0.14mmol) and the product of the last step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-oxybenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with a silica gel column (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized from ethyl acetate and petroleum ether to give 32mg of a white solid, the yield thereof was found to be 49%.1H NMR(300MHz,DMSO-d6)δ12.63(s,1H),10.11(s,1H),7.63-7.73(m,3H),7.44(t,1H,J＝8.1Hz),7.22-7.34(m,4H),7.10(d,1H,J＝8.7Hz),6.78-6.81(m,1H),3.80(s,1H),1.99-2.01(m,1H),0.93-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C26H19F4N3O4S[M+H]+:546.1105；found 546.1121.
Example 25
N- (6- (3- (2- (benzo [ d ] [1,3] dioxol-5-yl) acetamido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, substituting 3-trifluoromethylphenylacetic acid in the last step for piperonylic acid, dissolving piperonylic acid (25mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) in pyridine (10mL), adding 2- (7-benzotriazol-N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) to the solution at room temperature, stirring the mixture at 80 ℃ for 3h, concentrating the reaction mixture under reduced pressure, extracting with ethyl acetate, washing with saturated sodium chloride, drying over anhydrous sodium sulfate, filtering off the insoluble matter, drying under reduced pressure, purifying with silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), recrystallizing with ethyl acetate and petroleum ether to obtain a white solid 30mg, yield 50%.1H NMR(300MHz,DMSO-d6)δ12.62(s,1H),9.96(s,1H),7.63-7.73(m,3H),7.27(t,1H,J＝10.2Hz),7.10(dd,1H,J＝2.4,8.7Hz),6.74-6.86(m,4H),5.96(s,2H),3.62(s,1H),1.98-2.01(m,1H),0.93-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C26H20FN3O5S[M+H]+:506.1180；found 506.1189.
Example 26
N- (6- (4-fluoro-3- (2- (6- (trifluoromethyl) pyridin-2-yl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid was replaced with 2- (6- (trifluoromethyl) pyridin-2-yl in the last step]Acetic acid, 2- (6- (trifluoromethyl) pyridine-2-Base of]Acetic acid (29mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of the insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether to give 30mg of a white solid with a yield of 41%.1H NMR(300MHz,DMSO-d6)δ12.62(s,1H),10.21(s,1H),8.03(t,1H,J＝7.8Hz),7.64-7.73(m,5H),7.27(t,1H,J＝9.9Hz),7.10(dd,1H,J＝2.1,8.7Hz),6.79-6.83(m,1H),4.08(s,1H),1.98-2.01(m,1H),0.93-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C25H18F4N4O3S[M+H]+:531.1109；found 531.1120.
Example 27
N- (5- ((2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) -1- (3- (trifluoromethyl) phenyl) cyclopropane-1-carboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 1- (3- (trifluoromethyl) phenyl) cyclopropane-1-carboxylic acid, 1- (3- (trifluoromethyl) phenyl) cyclopropane-1-carboxylic acid (32mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-oxybenzotriazole) -N, N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1), recrystallization from ethyl acetate and petroleum ether gave 18mg of a white solid in 29% yield.1H NMR(300MHz,DMSO-d6)δ12.64(s,1H),8.62(s,1H),7.59-7.75(m,6H),7.28-7.31(m,1H),7.22(t,1H,J＝9.9Hz),7.10(dd,1H,J＝2.4,8.7Hz),6.82-6.87(m,1H),1.98-2.01(m,1H),1.48-1.52(m,2H),1.18-1.25(m,2H),0.91-0.97(m,4H)；MS(ESI):m/z[M+H]+:556.0.
Example 28
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclobutanecarboxamide
The previous four steps refer to example 12, the fifth step: n- (5- (2-aminobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (100mg, 0.27mmol) was dissolved in pyridine (10mL), cyclopropanecarbonyl chloride (64mg, 0.54mmol) was added slowly under nitrogen atmosphere, the reaction mixture was stirred at room temperature overnight, the reaction solution was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 75mg of a white solid in 70% yield. Sixth step and seventh step preparation referring to example 12,1H NMR(300MHz,DMSO-d6)δ12.20(s,1H),10.13(s,1H),7.68-7.71(m,3H),7.64(d,1H,J＝2.4Hz),7.54-7.61(m,3H),7.28(t,1H,J＝9.9Hz),7.10(dd,1H,J＝2.4,8.7Hz),6.77-6.82(m,1H),3.86(s,2H),3.67-3.42(m,1H),1.80-2.28(m,6H)；HRMS(ESI,positive)m/z calcd for C27H21F4N3O3S[M+H]+:544.1313；found 544.1330.
example 29
N- (6- (4-fluoro-3- (2- (1-methyl-1H-indol-3-yl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12, 3-trifluoromethylphenylacetic acid was replaced by 1-methyl-3-indole in the last stepAcetic acid, 1-methyl-3-indoleacetic acid (23mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-benzotriazole oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3h, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether to give 25mg of white solid in 38% yield.1H NMR(600MHz,DMSO-d6)δ12.59(s,1H),9.90(s,1H),7.69-7.72(m,2H),7.62(d,1H,J＝2.4Hz),7.57-7.59(m,1H),7.37-7.38(m,1H),7.24-7.27(m,1H),7.21(s,1H),7.11-7.14(m,1H),7.09(dd,1H,J＝3,9Hz),6.99-7.01(m,1H),6.75-6.78(m,1H),3.80(s,2H),3.74(s,3H),1.97-1.99(m,1H),0.93-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C28H23FN4O3S[M+H]+:515.1548；found 515.1560.
Example 30
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopentanecarboxamide
The previous four steps refer to example 12, the fifth step: n- (5- (2-aminobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (100mg, 0.27mmol) was dissolved in pyridine (10mL), cyclobutylcarbonyl chloride (71mg, 0.54mmol) was added slowly under nitrogen atmosphere, stirred at room temperature overnight, the reaction solution was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 80mg of a white solid in a yield of 72%. Sixth step and seventh step preparation referring to example 12,1H NMR(600MHz,DMSO-d6)δ12.30(s,1H),10.11(s,1H),7.67-7.74(m,3H),7.63(d,1H,J＝1.8Hz),7.53-7.61(m,3H),7.27(t,1H,J＝7.2Hz),7.10(dd,1H,J＝1.8,8.4Hz),6.78-6.80(m,1H),3.86(s,2H),2.95-2.98(m,1H),1.55-1.91(m,4H)；HRMS(ESI,positive)m/z calcd for C28H23F4N3O3S[M+H]+:558.1649；found 558.1477.
example 31
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) isobutyramide
The previous four steps refer to example 12, the fifth step: n- (5- (2-aminobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (100mg, 0.27mmol) was dissolved in pyridine (10mL), isopropanoyl chloride (57mg, 0.54mmol) was added slowly under nitrogen, stirred at room temperature overnight, the reaction was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 113mg of a white solid in a yield of 95%. Sixth step and seventh step preparation referring to example 12,1H NMR(300MHz,DMSO-d6)δ12.30(s,1H),10.14(s,1H),7.68-7.73(m,3H),7.64(d,1H,J＝2.4Hz),7.53-7.62(m,3H),7.28(t,1H,J＝10.2Hz),7.10(dd,1H,J＝2.4,9.3Hz),6.77-6.82(m,1H),3.86(s,2H),2.74-2.83(m,1H),1.13-1.18(m,4H)；HRMS(ESI,positive)m/z calcd for C26H21F4N3O3S[M+H]+:532.1313；found 532.1325.
example 32
N- (6- (3- (2- (3-cyanophenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation of reference example 12 by substituting 3-trifluoromethylphenylacetic acid for 3-cyanophenylacetic acid in the last step3-cyanophenylacetic acid (23mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-oxybenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether to give 32mg of white solid, yield 55%.1H NMR(300MHz,DMSO-d6)δ12.62(s,1H),10.12(s,1H),7.70-7.14(m,4H),7.62-7.64(m,2H),7.51(t,1H,J＝7.8Hz),7.28(t,1H,J＝9.9Hz,),7.09(dd,1H,J＝2.1,8.7Hz,q),6.77-6.82(m,1H),3.83(s,2H),1.98-2.21(m,1H),0.93-0.95(m,4H)；HRMS(ESI,positive)m/z calcd for C26H19FN4O3S[M+H]+:487.1352；found 487.1244.
Example 33
N- (6- (3- (2- (3, 4-dimethylphenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3, 4-dimethylphenylacetic acid, 3, 4-dimethylphenylacetic acid (23mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), 2- (7-oxybenzotriazole) -N, N' -tetramethylurea hexafluorophosphate (91mg, 0.24mmol) was added to the solution at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with a silica gel column (eluent: petroleum ether/ethyl acetate ═ 1:1), recrystallized with ethyl acetate and petroleum ether to give 26mg of a white solid, the yield thereof was found to be 45%.1H NMR(300MHz,DMSO-d6)δ12.63(s,1H),9.96(s,1H),7.70-7.72(m,1H),7.62(d,1H,J＝2.1Hz),7.26(t,1H,J＝9.9Hz),6.99-7.11(m,4H),6.76-6.80(m,1H),6.77-6.80(m,1H),3.63(s,2H),2.15-2.16(m,6H),1.98-2.01(m,1H),0.94-0.96(m,4H)；HRMS(ESI,positive)m/z calcd for C27H24FN3O3S[M+H]+:490.1595；found 490.1597.
Example 34
N- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) tetrahydro-2H-pyran-4-carboxamide
The previous four steps refer to example 12, the fifth step: n- (5- (2-aminobenzo [ d ]]Thiazol-6-yl) oxy) -2-fluorophenyl) -2,2, 2-trifluoroacetamide (100mg, 0.27mmol) was dissolved in pyridine (10mL), tetrahydropyran-4-carbonyl chloride (80mg, 0.54mmol) was added slowly under nitrogen atmosphere, stirred at room temperature overnight, the reaction solution was evaporated to dryness directly, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 3: 1-2: 1) to give 128mg of a white solid in 98% yield. Sixth step and seventh step preparation referring to example 12,1H NMR(300MHz,DMSO-d6)δ12.35(s,1H),10.13(s,1H),7.68-7.73(m,3H),7.64(d,1H,J＝2.4Hz),7.53-7.61(m,3H),7.28(t,1H,J＝10.2Hz),7.10(dd,1H,J＝2.4,8.7Hz),6.77-6.80(m,1H),3.86-3.92(m,4H),3.35-3.72(m,2H),2.76-2.83(m,1H),1.68-1.79(m,4H)；HRMS(ESI,positive)m/z calcd for C28H23F4N3O4S[M+H]+:574.1418；found 574.1428.
example 35
N- (6- (4-fluoro-3- (2- (3-hydroxyphenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Preparation reference example 12, 3-trifluoromethylphenylacetic acid in the last step was replaced with 3-hydroxyphenylacetic acid, 3-hydroxyphenylacetic acid (21mg, 0.14mmol) and the product of the previous step (30mg, 0.08mmol) were dissolved in pyridine (10mL), to the solution was added 2- (7-benzotriazol oxide) -N, N' -tetramethyluronium hexafluorophosphate (91mg, 0.24mmol) at room temperature, the mixture was stirred at 80 ℃ for 3 hours, the reaction mixture was concentrated under reduced pressure, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), and recrystallized with ethyl acetate and petroleum ether to give 26mg of a white solid with a yield of 46%.1H NMR(300MHz,DMSO-d6)δ12.63(s,1H),9.99(s,1H),9.33(s,1H),7.70-7.75(m,2H),7.64(d,1H,J＝2.4Hz),7.27(t,1H,J＝10.5Hz),7.05-7.12(m,2H),6.70-6.80(m,3H),6.62(d,1H,J＝9Hz),3.62(s,1H)1.98-1.99(m,1H),0.93-0.95(m,4H)；MS(ESI):m/z[M+H]+:478.0.
Example 36
N- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
The synthetic route is as follows:
step g-1: synthesis of N- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropane carboxamide.
The compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), the compound 1-isocyanato-3- (trifluoromethyl) benzene (32mg, 0.17mmol) was added and stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, the insoluble filtered, dried under reduced pressure and purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), giving 20mg of a pale yellow solid in 32% yield.1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),9.43(s,1H),8.75(s,1H),7.90-7.93(m,2H),7.72(d,1H,J＝9Hz),7.63(d,1H,J＝2.4Hz),7.49-7.53(m,2H),7.25-7.32(m,2H),7.12(dd,1H,J＝2.4,9Hz),6.66-6.68(m,1H),1.97-2.01(m,1H),0.94-0.96(m,4H).HRMS(ESI,positive)m/z calcd for C25H18F4N4O3S[M+H]+:531.1109；found 531.1118.
Example 37
N- (6- (4-fluoro-3- (3- (4- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 4-trifluoromethoxyphenyl isocyanate (34mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of the insoluble, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1) to give 3mg of a pale yellow solid in a yield of 0.04%.1H NMR(300MHz,DMSO-d6)δ12.63(s,1H),9.29(s,1H),8.71(s,1H),7.90(dd,1H,J＝2.7,6.6Hz),7.74(d,1H,J＝8.7Hz),7.66(d,1H,J＝2.1Hz),7.49-7.54(m,2H),7.23-7.30(m,3H),7.13(dd,1H,J＝2.1,8.7Hz),6.64-6.69(m,1H),1.91-2.04(m,1H),0.94-0.97(m,4H)；HRMS(ESI,positive)m/z calcd for C25H20FN3O4S[M+H]+:547.1058；found 547.1066.
Example 38
N- (6- (4-fluoro-3- (3- (3-methoxyphenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
By referring to the synthetic route of example 36, willCompound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 3-methoxyphenyl isocyanate (25mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of the insoluble, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1) to give 32mg of a pale yellow solid in a yield of 54%.1H NMR(600MHz,DMSO-d6)δ12.81(s,1H),9.12(s,1H),8.86(s,1H),7.90-7.93(m,1H),7.72(d,1H,J＝8.4Hz),7.63(d,1H,J＝2.4Hz),7.23-7.27(m,1H),7.10-7.18(m,3H),6.89(d,1H,J＝9.6Hz),6.63-6.65(m,1H),6.57(dd,1H,J＝1.2,7.2Hz),3.71(s,3H),1.97-2.01(m,1H),0.93-0.96(m,4H)；
Example 39
N- (6- (4-fluoro-3- (3- (m-tolyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 3-methylphenyl isocyanate (23mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of the insoluble, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1) to give 32mg of a pale yellow solid in a yield of 56%.1H NMR(600MHz,DMSO-d6)δ12.62(s,1H),9.03(s,1H),8.65(s,1H),7.95-7.96(m,1H),7.72(d,1H,J＝8.4Hz),7.63(d,1H,J＝2.4Hz),7.11-7.27(m,5H),6.78(d,1H,J＝7.2Hz),6.62-6.65(m,1H),2.25(s,3H),1.98-2.01(m,1H),0.94-0.95(m,4H).
Example 40
3- (3- (5- ((2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) ureido) benzoic acid ethyl ester
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), then 3- (ethoxycarbonyl) phenyl isocyanate (30mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), yielding 35mg of a pale yellow solid in 55% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),9.35(s,1H),8.66(s,1H),8.07-8,.08(m,1H),7.91-7.93(m,1H),7.73(d,1H,J＝9Hz),7.65(d,1H,J＝3.6Hz),7.56-7.61(m,2H),7.41(t,1H,J＝8.4Hz),7.24-7.28(m,1H),7.12-7.14(m,1H),6.65-6.68(m,1H),4.29(q,2H,J＝7.2Hz),1.98-2.01(m,1H),1.30(t,3H,J＝7.2Hz),0.94-0.95(m,4H).
EXAMPLE 41
N- (6- (3- (3- (3-acetylphenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 3-acetylphenyl isocyanate (27mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified with silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), yielding 30mg of a pale yellow solid in 50% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),9.32(s,1H),8.69(s,1H),7.98(t,1H,J＝2.4Hz),7.91-7.93(m,1H),7.73(d,1H,J＝9Hz),7.58-7.65(m,3H),7.42(t,1H,J＝7.8Hz),7.25-7.28(m,1H),7.12(dd,1H,J＝2.4,8.4Hz),6.65-6.67(m,1H),2.54(s,3H),1.97-2.01(m,1H),0.93-0.96(m,4H).
Example 42
N- (6- (3- (3- (3-bromophenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 3-bromophenyl isocyanate (30mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of insoluble matter, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate ═ 1:1), yielding 35mg of a pale yellow solid in 54% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),9.26(s,1H),8.71(s,1H),7.89-7.91(m,1H),7.79(t,1H,J＝1.8Hz),7.73(d,1H,J＝8.4Hz),7.63(d,1H,J＝2.4Hz),7.21-7.27(m,3H),7.12-7.16(m,2H),6.65-6.68(m,1H),1.99-2.01(m,1H),0.94-0.96(m,4H).
Example 43
N- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) thioureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 36, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) was dissolved in DMF (5mL), 3- (trifluoromethyl) phenyl isothiocyanate (34mg, 0.17mmol) was added, stirred at room temperature for 12h, diluted with ethyl acetate, washed with sodium bicarbonate solution and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered of the insoluble, dried under reduced pressure, purified by silica gel chromatography (eluent: petroleum ether/ethyl acetate 1:1) to obtainTo a pale yellow solid, 12mg, yield 18%.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),10.22(s,1H),9.78(s,1H),7.94-7.95(m,1H),7.72-7.75(m,2H),7.66(d,1H,J＝2.4Hz),7.56(t,1H,J＝7.8Hz),7.46-7.49(m,1H),7.37-7.38(m,1H),7.28-7.31(m,1H),7.14(dd,1H,J＝2.4,8.4Hz),6.92-6.95(m,1H),1.97-2.01(m,1H),0.93-0.96(m,4H).
Example 44
N- (6- (4-fluoro-3- (3- (3- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
The synthetic route is as follows:
step g-2 Synthesis of N- (6- (4-fluoro-3- (3- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide.
3- (trifluoromethoxy) aniline (50mg, 0.28mmol) was dissolved in dry DCM (5mL), triethylamine (56mg, 0.52mmol) and triphosgene (27mg, 0.094mmol) were added to the reaction solution, and after stirring at room temperature for three hours, N- (6- (3-amino-4-fluorophenoxy) benzo [ d ] was added to the reaction solution]Thiazol-2-yl) cyclopropanecarboxamide (96mg, 0.28mmol) was reacted for 2h, the reaction was evaporated to dryness and the residue was purified directly on a chromatographic column (eluent: dichloromethane/methanol 100:3) to yield 32mg of a white solid in 20% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),9.40(s,1H),8.73(s,1H),7.89-7.91(m,1H),7.72(d,1H,J＝8.4Hz),7.61-7.64(m,2H),7.39(t,1H,J＝8.4Hz),7.24-7.29(m,2H),7.12(dd,1H,J＝2.4,8.4Hz),6.94-6.96(m,1H),6.65-6.68(m,1H),1.97-2.01(m,1H),0.93-0.96(m,4H).
Example 45
N- (6- (4-fluoro-3- (3- (6- (trifluoromethyl) pyridin-2-yl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 44, 2-amino-6- (trifluoromethyl) pyridine (45mg, 0.28mmol) was dissolved in dry DCM (5mL), triethylamine (56mg, 0.52mmol) and triphosgene (27mg, 0.094mmol) were added to the reaction solution, and after stirring at room temperature for three hours, N- (6- (3-amino-4-fluorophenoxy) benzo [ d ] was added to the reaction solution]Thiazol-2-yl) cyclopropanecarboxamide (96mg, 0.28mmol) was reacted for 2h, the reaction was evaporated to dryness and the residue was purified directly on a chromatographic column (eluent: dichloromethane/methanol 100:3) to yield 30mg of a white solid in 20% yield.1H NMR(600MHz,DMSO-d6)δ12.61(s,1H),10.25(s,1H),10.09(s,1H),7.97-8.02(m,2H),7.80-7.81(m,1H),7.73(d,1H,J＝8.4Hz),7.65(d,1H,J＝2.4Hz),7.51(d,1H,J＝7.8Hz),7.28-7.31(m,1H),7.13(dd,1H,J＝3,8.4Hz),6.70-6.72(m,1H),1.97-2.01(m,1H),0.93-0.96(m,4H).
Example 46
N- (6- (4-fluoro-3- ((3- (trifluoromethyl) benzyl) amino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
The synthetic route is as follows:
step g-3: synthesis of N- (6- (4-fluoro-3- ((3- (trifluoromethyl) benzyl) amino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide.
The compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) and 3- (trifluoromethyl) benzaldehyde (21mg, 0.12mmol) were dissolved in methanol (5mL) and 1 drop of acetic acid was added for catalysis, stirred at room temperature overnight, sodium cyanoborohydride (15mg, 0.24mmol) was added, stirred overnight, the solvent was evaporated to dryness, purified by silica gel chromatography (eluent: dichloromethane/methanol 100:3) to yield 19mg of a white solid in 32% yield.1HNMR(300MHz,DMSO-d6)δ12.59(s,1H),7.44-7.65(m,6H),6.91-7.04(m,2H),6.55(d,1H,J＝5.1Hz),6.25(dd,1H,J＝2.4,7.2Hz),6.08-6.10(m,1H),4.38(d,2H,J＝5.7Hz),1.98-2.02(m,1H),0.93-0.94(m,4H)；HRMS(ESI,positive)m/z calcd for C25H19F4N3O2S[M-H]-:500.1061；found 500.1046.
Example 47
N- (6- (3- ((benzo [ d ] [1,3] dioxol-5-ylmethyl) amino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
Referring to the synthetic route of example 46, the compound N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (40mg, 0.12mmol) and piperonal (18mg, 0.12mmol) were dissolved in methanol (5mL) and 1 drop of acetic acid was added for catalysis, stirred at room temperature overnight, sodium cyanoborohydride (15mg, 0.24mmol) was added, stirred overnight, the solvent was evaporated to dryness, purified by silica gel chromatography (eluent: dichloromethane/methanol 100:3) to yield 15mg of a white solid in 26% yield.1H NMR(300MHz,DMSO-d6)δ12.59(s,1H),7.64(d,1H,J＝8.7Hz),7.47(d,1H,J＝2.1Hz),6.95-7.01(m,2H),6.84-6.85(m,1H),6.69-6.78(m,2H),6.30-6.41(m,1H),6.23(dd,1H,J＝2.7,7.5Hz),6.05-6.10(m,1H),5.95-5.97(s,2H),4.17(d,2H,J＝5.4Hz),1.95-2.04(m,1H),0.93-0.96(m,4H)；MS(ESI):m/z[M+H]+:478.0.
Example 48
N- (6- (4-fluoro-3- ((3- (trifluoromethyl) phenyl) sulfonamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide
The synthetic route is as follows:
step g-4: synthesis of N- (6- (4-fluoro-3- ((3- (trifluoromethyl) phenyl) sulfonamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide.
N- (6- (3-amino-4-fluorophenoxy) benzo [ d]Thiazol-2-yl) cyclopropanecarboxamide (50mg, 0.14mmol) was dissolved in pyridine (10mL), and 3- (trifluoro-3) was slowly added under a nitrogen atmosphereMethyl) benzenesulfonyl chloride (68mg, 0.28mmol), stirred at room temperature overnight, the reaction solution was directly evaporated to dryness, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the residue was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 2: 1-1: 1) to give 32mg of a white solid in 42% yield.1H NMR(600MHz,DMSO-d6)δ12.64(s,1H),10.48(s,1H),8.01(d,1H,J＝7.8Hz),7.94-7.98(m,2H),7.80(t,1H,J＝7.8Hz),7.71(d,1H,J＝8.4Hz),7.60(d,1H,J＝3Hz),7.20(t,1H,J＝9.6Hz),7.01(dd,1H,J＝2.4,9Hz),6.88-6.91(m,1H),6.74-6.75(m,1H),1.98-2.01(m,1H),0.95-0.96(m,4H)；MS(ESI):m/z[M+H]+:551.9.
Example 49
RPK1, RIPK3 kinase assays
Using KINOMEscanTMThe kinase activity of the synthetic compounds and partial intermediates of examples 1-48 of the invention, and the comparative compound TAK-632 on RIPK1 and RIPK3 was tested by the RIPK1 and RIPK3 kinase detection methods.
DNA-labeled RIPK1 and RIPK3 kinase-labeled T7 phage strain lysates were detected using qPCR. The kinase, ligand affinity beads and test compound were combined in binding buffer (20% SeaBlock, 0.17 × PBS, 0.05% Tween 20, 6mM DTT). The compounds were diluted 3-fold, set at 10 points, incubated with shaking for 1h at room temperature, and the beads were washed with wash buffer (1 × PBS, 0.05% Tween 20), then resuspended in elution buffer (1 × PBS, 0.05% Tween 20, 0.5 μ M non-biotinylated affinity ligand), and incubated with shaking for 30min at room temperature. K was calculated by qPCR measurement of kinase concentration in the eluatedThe values, calculated as follows (Hill Slope set to-1), are shown in Table 1:
example 50
Anti-apoptosis assay
Tumor cells were induced by addition of TNF-. alpha. (20ng/ml) after 30min pretreatment with z-VAD-fmk (20. mu.M) and Smac mimic (10nM)Necrosis of the head. The synthetic compounds of examples 1-48 of the invention, the comparative compound TAK-632, and the cells of the combination were incubated for 16 hours. Cell activity was tested using the CellTiter-Glo luminescent cell viability assay kit (Promega). Chemiluminescence values were recorded using a BioTek 312e microplate reader (BioTek Instruments, Winooski, VT) and IC calculated50The values, results are shown in Table 1.
TABLE 1 RIPK1, RIPK3 kinase Activity and anti-apoptotic Activity of Compounds
N.d. means no test
The experimental results show that the benzothiazole derivative has excellent anti-cell necrosis activity, is obviously superior to positive control TAK-632, has different degrees of RIPK activity improved compared with TAK-632, can be used as an RIPK1/RIPK3 double-target inhibitor or an RIPK1/RIPK3 selective inhibitor, is used for preparing anti-TNF-induced systemic immune syndrome (SIRS) and anti-acetaminophen (APAP) -induced hepatotoxicity drugs, and is used for preparing anti-Alzheimer disease, anti-ischemic cardiomyopathy, anti-ischemic stroke, anti-atherosclerosis, anti-acute pancreatitis, anti-children inflammatory bowel disease, anti-sepsis, anti-Salmonella infection, anti-Listeria infection, anti-vaccinia virus infection and other inflammation or infection related diseases.
Therefore, the compound and the salt thereof can be used for preparing the anti-programmed cell necrosis inhibitor.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are given by way of illustration of the principles of the present invention, and that various changes and modifications may be made without departing from the spirit and scope of the invention as defined by the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (7)
1. A benzothiazole derivative, characterized in that: the benzothiazole derivative is selected from one of the following structures:
n- (7-cyano-6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (2-fluoro-3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (3, 5-bis (trifluoromethyl) phenyl) acetamido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3-nitrophenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclohexanecarboxamide;
n- (6- (4-fluoro-3- (2- (2- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (m-tolyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) propionylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (pyridin-2-yl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (4-fluoro-3 (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3-methoxyphenyl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethoxy) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (benzo [ d ] [1,3] dioxol-5-yl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (6- (trifluoromethyl) pyridin-2-yl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclobutanecarboxamide;
n- (6- (4-fluoro-3- (2- (1-methyl-1H-indol-3-yl) acetylamino) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopentanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) isobutyramide;
n- (6- (3- (2- (3-cyanophenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (2- (3, 4-dimethylphenyl) acetylamino) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (2- (3- (trifluoromethyl) phenyl) acetamido) phenoxy) benzo [ d ] thiazol-2-yl) tetrahydro-2H-pyran-4-carboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (4- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3-methoxyphenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (m-tolyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
ethyl 3- (3- (5- ((2- (cyclopropanecarboxamido) benzo [ d ] thiazol-6-yl) oxy) -2-fluorophenyl) ureido) benzoate;
n- (6- (3- (3- (3-acetylphenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (3- (3- (3-bromophenyl) ureido) -4-fluorophenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethyl) phenyl) thioureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide;
n- (6- (4-fluoro-3- (3- (3- (trifluoromethoxy) phenyl) ureido) phenoxy) benzo [ d ] thiazol-2-yl) cyclopropanecarboxamide.
2. Use of the benzothiazole derivatives of claim 1 in the preparation of RIPK1 or RIPK3 kinase inhibitors.
3. Use of the benzothiazole derivative according to claim 1 for preparing an inhibitor of programmed cell necrosis.
4. Use of the benzothiazole derivatives according to claim 1 in the preparation of drugs for the prevention and treatment of diseases associated with programmed cell necrosis, or for the preparation of drugs for inflammatory, infectious, ischemic or degenerative related diseases or tissue injuries caused by RIPK1 or RIPK3 kinase disorders, overactivation or overactive interactions.
5. Use according to claim 4, characterized in that: the inflammatory, infectious, ischemic or degenerative related diseases or tissue damage is mediated by RIPK1/RIPK3 kinase, or is initiated by programmed cell necrosis.
6. Use according to claim 4, characterized in that: the inflammatory, infectious, ischemic or degenerative related diseases are selected from: systemic inflammatory syndrome, acetaminophen-induced tissue damage, acute pancreatitis, inflammatory bowel disease, sepsis, salmonella infection, listeria infection, vaccinia virus infection, alzheimer's disease, ischemic cardiomyopathy, ischemic stroke, atherosclerosis.
7. A pharmaceutical composition characterized by: comprising the benzothiazole derivative of claim 1 and a pharmaceutically acceptable excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810958721.1A CN109053630B (en) | 2018-08-22 | 2018-08-22 | Benzothiazole derivative and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810958721.1A CN109053630B (en) | 2018-08-22 | 2018-08-22 | Benzothiazole derivative and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109053630A CN109053630A (en) | 2018-12-21 |
| CN109053630B true CN109053630B (en) | 2022-04-01 |
Family
ID=64687839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810958721.1A Active CN109053630B (en) | 2018-08-22 | 2018-08-22 | Benzothiazole derivative and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109053630B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3943488A4 (en) * | 2019-03-22 | 2022-09-07 | Genfleet Therapeutics (Shanghai) Inc. | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND METHOD OF MANUFACTURE THEREOF AND PHARMACEUTICAL USE THEREOF |
| CN115624547A (en) * | 2020-06-12 | 2023-01-20 | 子辰海洋医药科技(上海)有限公司 | A kind of sesquiterpene compound and its preparation method and application |
| CN112094248B (en) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | A kind of substituted benzothiazole compound and its use |
| CN114989079B (en) * | 2022-06-21 | 2023-06-23 | 中国药科大学 | RIPK1 kinase target inhibitor and medical application thereof |
| CN116332871B (en) * | 2023-02-20 | 2024-09-20 | 中国人民解放军海军军医大学 | Cyclohexyl substituted benzothiazole derivative for inhibiting programmed cell necrosis and application thereof |
| CN119119035A (en) * | 2024-08-30 | 2024-12-13 | 中山大学 | A RIPK1 kinase target inhibitor and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102300854A (en) * | 2008-12-02 | 2011-12-28 | 武田药品工业株式会社 | Benzothiazole derivatives as anticancer agents |
| CN107753483A (en) * | 2016-08-19 | 2018-03-06 | 爱科诺生物医药股份有限公司 | Medicine and its application with meronecrosis inhibitory activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009025358A1 (en) * | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US9248185B2 (en) * | 2011-06-16 | 2016-02-02 | President And Fellows Of Harvard College | Methods of increasing satellite cell proliferation |
-
2018
- 2018-08-22 CN CN201810958721.1A patent/CN109053630B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102300854A (en) * | 2008-12-02 | 2011-12-28 | 武田药品工业株式会社 | Benzothiazole derivatives as anticancer agents |
| CN107753483A (en) * | 2016-08-19 | 2018-03-06 | 爱科诺生物医药股份有限公司 | Medicine and its application with meronecrosis inhibitory activity |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C‑7-Substituted 1,3-Benzothiazole Derivatives;Masanori Okaniwa et al.;《J. Med. Chem.》;20130801;第56卷;第6478-6494页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109053630A (en) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109053630B (en) | Benzothiazole derivative and application thereof | |
| RU2339614C2 (en) | Acidified indanylamines and their use as pharmaceutical preparations | |
| RU2453536C2 (en) | Histone deacetylase inhibitors | |
| JP2006518341A (en) | Hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors | |
| CA2494628C (en) | Acylated arylcycloalkylamines and their use as pharmaceuticals | |
| CA2838703C (en) | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | |
| JP2011503178A (en) | Bis- (sulfonylamino) derivatives in therapy 066 | |
| JP2000513386A (en) | Indole compounds as COX-2 inhibitors | |
| CN105884767B (en) | Pyrido [3,4 b] indole derivatives of 9 substitutions and preparation method thereof and the purposes as SIRT protein inhibitors | |
| WO2011145669A1 (en) | Amide derivative | |
| JP2007261945A (en) | Thiazole derivative | |
| US6420426B1 (en) | Substituted phenoxyacetic acids | |
| WO2019196714A1 (en) | N-substituted acrylamide derivative as dhodh inhibitor, and preparation and use thereof | |
| CN113061098A (en) | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | |
| JP5253174B2 (en) | N-phenyloxamic acid derivatives | |
| WO2001027096A1 (en) | Aminomethyl-(hetero)aryl derivatives and their use as tryptase inhibitors | |
| JP6293168B2 (en) | Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for producing the same, and pharmaceutical composition for preventing or treating viral diseases containing the same as an active ingredient | |
| KR20210021830A (en) | Novel compound with cancer metastasis inhibiting activity, method for preparing the same and pharmaceutical composition for inhibiting cancer metastasis and invasion or treating colon cancer | |
| CN109293606B (en) | 2, 5-disubstituted furan derivative and application thereof as SIRT protein inhibitor in preparation of medicines | |
| EP4349818A1 (en) | Novel oxazole derivative and pharmaceutical composition containing same for prevention or treatment of allergic disease | |
| JP4078494B2 (en) | Hepatitis C drug | |
| JP7065898B2 (en) | New compounds, their preparation and their therapeutic use | |
| HK40018321A (en) | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | |
| WO2024140671A1 (en) | Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof | |
| RU2574591C2 (en) | Indanone derivative, its pharmaceutically acceptable salt or enantiomer, method for producing it and pharmaceutical composition containing it and applicable for preventing or treating viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |